ReviewMalaria journal2017
Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways.
Review in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis.The Lancet. Global health · 2020Pooled it
- Trial
- Ivermectin to reduce malaria transmission- safety and efficacy results from the BOHEMIA cluster randomized trial in Mozambique.EClinicalMedicine · 2025Article
- Through the eyes of the participant: using photovoice to understand the experiences and effects of ivermectin MDA in the context of the BOHEMIA clinical trial in Kwale, Kenya.Malaria journal · 2025Article
- Effect of fluralaner on the biology, survival, and reproductive fitness of the neotropical malaria vector Anopheles aquasalis.Malaria journal · 2023Article
- Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.Current research in translational medicine · 2021Review
- Costs and barriers faced by households seeking malaria treatment in the Upper River Region, The Gambia.Malaria journal · 2021Article
- Potential metabolic resistance mechanisms to ivermectin in Anopheles gambiae: a synergist bioassay study.Parasites & vectors · 2021Article
- Veterinary endectocides for malaria control and elimination: prospects and challenges.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2021Article
- Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation.Heliyon · 2021Article
- A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.The American journal of tropical medicine and hygiene · 2020Article
- Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparumAntimicrobial agents and chemotherapy · 2019Article
- Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation.Parasites & vectors · 2018Article
- Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway.Malaria journal · 2017Review
- Ivermectin and malaria control.Malaria journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vector control is a task previously relegated to products that (a) kill the mosquitoes directly at different stages (insecticides, larvicides, baited traps), or (b) avoid/reduce human-mosquito contact (bed nets, repellents, house screening), thereby reducing transmission. The potential community-based administration of the endectocide ivermectin with the intent to kill mosquitoes that bite humans, and thus reduce malaria transmission, offers a novel approach using a well-known drug, but additional steps are required to address technical, regulatory and policy gaps. The proposed community administration of this drug presents dual novel paradigms; first, indirect impact on the community rather than on individuals, and second, the use of a drug for vector control. In this paper, the main questions related to the regulatory and policy pathways for such an application are identified. Succinct answers are proposed for how the efficacy, safety, acceptability, cost-effectiveness and programmatic suitability could result in regulatory approval and ultimately policy recommendations on the use of ivermectin as a complementary vector control tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.